Holen Sie sich die Stockscreener-App
181.34
2.40%
-4.45
Schlusskurs vom Vortag:
$185.79
Offen:
$187.18
24-Stunden-Volumen:
519.31K
Relative Volume:
0.59
Marktkapitalisierung:
$8.73B
Einnahmen:
$4.02B
Nettoeinkommen (Verlust:
$-142.16M
KGV:
-61.34
EPS:
-2.9563
Netto-Cashflow:
$518.49M
1W Leistung:
+0.35%
1M Leistung:
-2.18%
6M Leistung:
-1.61%
1J Leistung:
+28.43%
1-Tages-Spanne:
$180.55
$187.35
1-Wochen-Bereich:
$169.46
$187.95
52-Wochen-Spanne:
$143.06
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
181.34 | 8.95B | 4.02B | -142.16M | 518.49M | -2.9563 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-17 | Hochstufung | Argus | Hold → Buy |
| 2025-11-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MSN
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Can Charles River’s Portfolio Divestitures and “Pathway to Purpose” Strategy Reframe the CRL Investment Narrative? - simplywall.st
Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says - marketscreener.com
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River (CRL) director awarded 422 restricted stock units as fees - Stock Titan
CRL: New strategy targets margin gains, tech integration, and growth, with DSA momentum building - TradingView
Charles River Laboratories International Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
Charles River Laboratories International, Inc. (CRL) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow (NYSE:CRL) 2026-06-03 - Seeking Alpha
Preclinical CRO Market Size, Share, Growth, Analysis, Report, 2034 - Straits Research
Charles River Laboratories International Inc (CRL) Shares Fall 4 - GuruFocus
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
CRL (CRL) CFO Glenn Coleman receives 6,640-share equity grant at $180.71 - Stock Titan
CRL (NYSE: CRL) CIO receives stock grant; shares withheld for taxes - Stock Titan
Charles River (NYSE: CRL) EVP awarded 5,257 shares, 979 withheld - Stock Titan
CRL (NYSE: CRL) SVP Michael Knell awarded 1,837 shares, 200 used for tax withholding - Stock Titan
Charles River (NYSE: CRL) CEO awarded shares, withholds stock to pay tax - Stock Titan
James C. Foster (CRL) records tax-withholding share disposition and updates indirect holdings - Stock Titan
Charles River (NYSE: CRL) EVP gets 5,135-share award with tax withholding - Stock Titan
Charles River (NYSE: CRL) executive reports stock grant and tax withholding - Stock Titan
CRL: Operational efficiency, innovation, and portfolio focus drive growth and resilience - TradingView
CRL: Modernization, AI, and NAMs drive growth and margin expansion, with renewed DSA momentum - TradingView
Charles River Laboratories International Inc at William Blair Growth Stock Conference Transcript - GuruFocus
Charles River Shareholder Notice - TMX Newsfile
Charles River Laboratories to Present at William Blair and Jefferies Conferences 2026 - BioSpace
Charles River Laboratories (CRL) to Present at Key Investor Conf - GuruFocus
Charles River Laboratories to Present at William Blair and Jefferies Conferences - pharmiweb.com
CLSA upgrades Charles River Laboratories International (CRL) - MSN
Charles River Laboratories (CRL) Slides Slightly, Holds Near Key ResistanceMarket Cap Weight - thelegaladvocate.com
Charles River Laboratories Hits Day High with 10.24% Surge in Stock Price - Markets Mojo
CLSA upgrades Charles River Labs stock rating on regulatory outlook - Investing.com UK
CLSA upgrades Charles River Labs stock rating on regulatory outlook By Investing.com - Investing.com Nigeria
[Form 4] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading Activity - Stock Titan
Charles River (NYSE: CRL) executive logs tax-share withholding and trust gift - Stock Titan
Charles River Laboratories International Jumps 7.9% in Broad Rally - AlphaStreet
CRL (CRL) CEO Girshick delivers 618 shares for tax withholding, holds over 71K - Stock Titan
Charles River (NYSE: CRL) finance executive reports small tax-withholding share moves - Stock Titan
Charles River (CRL) EVP LaPlume reports 428-share tax-withholding disposals - Stock Titan
Charles River Laboratories International Inc (CRL) Shares Surge 5.0% -- What GF Score of 72 Tells Investors - GuruFocus
Wall Street Analysts Weigh in on Charles River Laboratories: Mixed Sentiment PersistsCash Flow Report - The Legal Advocate
Are Wall Street analysts bullish on Charles River Laboratories stock? - MSN
Are Wall Street Analysts Bullish on Charles River Laboratories Stock? - Yahoo Finance
CRL Q1 2026 Earnings: EPS Surpasses Estimates Amid Resilient OperationsEarnings Deceleration Risk - thelegaladvocate.com
Charles River Laboratories Inte (CRL) Stock Analysis: A 30% Upside Potential Amidst Healthcare Sector Dynamics - DirectorsTalk Interviews
Cell Banking Outsourcing Market: 16%+ CAGR (2026-2031), Expanding with Rising Demand for Biologics and Regenerative Medicine Services, Says Mordor Intelligence - GlobeNewswire Inc.
Is Charles River (CRL) Quietly Recasting Its Moat Around AI Pathology And Cell Therapy Services? - Yahoo Finance
Should Higher Impairments and AI Investments Shape a New Capital Allocation Playbook for Charles River (CRL)? - simplywall.st
Charles River Laboratories (CRL) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
2.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):